Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus HYPAQUE SODIUM 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus HYPAQUE SODIUM 20.
HYPAQUE-CYSTO vs HYPAQUE SODIUM 20%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Hypaque sodium is an ionic monomeric iodinated contrast medium that absorbs X-rays due to its iodine content, providing radiographic contrast. It increases the density of vascular structures and organ parenchyma, allowing visualization during imaging procedures.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
Intravenous: 30-60 mL (6-12 g iodine) administered as a bolus or infusion for excretory urography; may be repeated up to a total of 125 mL (25 g iodine). Intra-arterial: Variable based on procedure, typically 8-30 mL for selective angiography.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment.
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Renal: >95% unchanged via glomerular filtration within 24 hours; <5% biliary/fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent